Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A), a Canadian corporation pioneering early detection of critical health issues through Artificial Intelligence-based technology, has announced an engagement with Investor Brand Network ("IBN") for corporate communication and awareness solutions. The one-year agreement, effective January 10, 2026, involves monthly compensation of US$6,400 payable in advance from the corporation's funds, with the engagement remaining subject to acceptance by the TSX Venture Exchange.
Under this arrangement, IBN will assist Diagnos in refining and strengthening its market awareness profile with the objective of maximizing shareholder value. The company has confirmed that IBN is acting at arm's length and, together with its principals, holds no direct or indirect interest in Diagnos securities. This corporate communications initiative comes as Diagnos continues to develop its AI technology platform aimed at early detection of critical eye-related health problems, providing healthcare clinicians with enhanced diagnostic tools to improve patient outcomes globally.
The engagement with IBN represents a strategic move by Diagnos to increase visibility within the investment community and broader market. Investor Brand Network operates as a specialized communications platform within the Dynamic Brand Portfolio @ IBN, offering advanced wire-grade press release syndication for both private and public companies. The network provides access to wire solutions reaching diverse target markets and demographics, along with article and editorial syndication to more than 5,000 outlets, enhanced press release services, and social media distribution to millions of followers.
For investors and stakeholders, this development signals Diagnos's commitment to strengthening its corporate communications strategy as the company advances its AI-based healthcare solutions. The partnership with IBN could potentially increase market awareness of Diagnos's technology platform, which aims to transform early detection of eye health issues through artificial intelligence. Additional information about Diagnos is available through the company's website at https://www.diagnos.com and through regulatory filings at https://www.sedarplus.com.
The broader implications of this corporate communications engagement extend to how emerging healthcare technology companies navigate market visibility challenges. As AI-based medical diagnostics continue to evolve, effective communication strategies become increasingly important for companies seeking to demonstrate value to both healthcare providers and investment communities. The Investor Brand Network platform, which can be explored further at https://www.InvestorWire.com, specializes in helping companies cut through information overload to achieve recognition and brand awareness in competitive markets.
This corporate development occurs within a healthcare technology sector where clear communication of technological advancements and business strategies can significantly impact investor confidence and market positioning. For Diagnos, which focuses on leveraging Artificial Intelligence to enhance diagnostic accuracy and streamline clinical workflows, the engagement with IBN represents a calculated step toward broader market recognition as the company continues to develop its early detection solutions for critical eye health conditions.
